Investors Face Losses as Erasca Faces Securities Class Action

The legal action, Cheng v. Erasca, Inc., centers on claims that the company misled shareholders regarding its precision oncology candidate, ERAS-0015. According to the complaint, Erasca allegedly used improper preclinical data comparisons to Revolution Medicines, Inc., potentially infringing on trade secrets and patents. These disclosures, compounded by the report of a patient death during Phase I trials, triggered significant market volatility. Erasca stock dropped nearly 11% following the patent infringement news and plummeted an additional 48% after the company clarified that its comparative data lacked head-to-head clinical trial validation.

Robbins Geller Rudman & Dowd LLP is spearheading the case for shareholders seeking recovery. Under the Private Securities Litigation Reform Act, the lead plaintiff acts on behalf of the class, typically representing the investor with the largest financial stake. While participants do not need to serve as lead plaintiff to share in a potential recovery, the firm is currently soliciting information from those who suffered substantial losses during the specified period.